<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355533</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200467</org_study_id>
    <secondary_id>2020-A00999-30</secondary_id>
    <nct_id>NCT04355533</nct_id>
  </id_info>
  <brief_title>Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19</brief_title>
  <acronym>PED-COVID</acronym>
  <official_title>Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commissariat a l'energie atomique et aux energies alternatives</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide data on the proportion of seroconverted children and&#xD;
      their immune status. It will also provide insight into the number of children currently&#xD;
      infected at each time point including healthy carriers. Investigators will provide similar&#xD;
      data on their parents in an ancillary study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fraction of undiagnosed but likely to transmit the virus is a critical epidemiological&#xD;
      characteristic that modulates the epidemic potential of SARS-CoV2. To adapt the epidemy&#xD;
      control, it is essential to study the immunoprotection of the general population. A crucial&#xD;
      question is the study of pauci or asymptomatic subjects, and in particular children who make&#xD;
      mild forms, because they could act as a real reservoir for the spread of the virus. The&#xD;
      serological study is essential in this context.&#xD;
&#xD;
      The serologic test Abbott will be used to study immunoprevalence. Institut Pasteur has&#xD;
      validated test using neutralizing Ab. CEA will used a antibodies and antigen test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion against SARS-CoV2 in children</measure>
    <time_frame>at inclusion</time_frame>
    <description>serology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Ab antiN and Ab anti-S1/2</measure>
    <time_frame>at inclusion</time_frame>
    <description>Serology in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralization activity</measure>
    <time_frame>at inclusion</time_frame>
    <description>Serology in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive qPCR in children</measure>
    <time_frame>at inclusion</time_frame>
    <description>in children, qualitative and quantitative measure , in nasopharynx, saliva and stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between different Ab and qPCR and neutralization activity</measure>
    <time_frame>at inclusion</time_frame>
    <description>in children, qualitative and quantitative measure , in nasopharynx, saliva and stool, Ab anti-N, Ab anti-S1/2, neutralization serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective immunity</measure>
    <time_frame>Day 7</time_frame>
    <description>Serology, measure of Ab in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective immunity</measure>
    <time_frame>Day 15</time_frame>
    <description>Serology, measure of Ab in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective immunity</measure>
    <time_frame>Day 30</time_frame>
    <description>Serology, measure of Ab in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective immunity</measure>
    <time_frame>At 6 months</time_frame>
    <description>Serology, measure of Ab in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective immunity</measure>
    <time_frame>At 12 months</time_frame>
    <description>Serology, measure of Ab in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of viral carriage in stool, saliva and or nasopharynx</measure>
    <time_frame>until 30 days post onset</time_frame>
    <description>Sars-Cov2 PCR in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between antibody profile and viral clearance</measure>
    <time_frame>until 30 days post onset</time_frame>
    <description>Serology in PCR positive children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>At Day 7</time_frame>
    <description>Immune cells in positive PCR children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>At Day 15</time_frame>
    <description>Immune cells in positive PCR children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>At Day 30</time_frame>
    <description>Immune cells in positive PCR children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>At 6 months</time_frame>
    <description>Immune cells in positive PCR children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>At 12 months</time_frame>
    <description>Immune cells in positive PCR children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva biofluid characteristics of COVID-19 infected</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>viral content (qPCR and immunodetection); presence of IgG, M, and A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of the virus</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>In PCR positive children: nasopharynx, saliva, stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>In PCR positive children: occurrence of reinfection, immunity responses during reinfection and potential mutations of the virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>At inclusion</time_frame>
    <description>In children COVID+ during the first wave :immune response few months after the infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal immunity</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>In PCR positive children: Ab anti-SARS-cov2 in nasopharynx samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroconversion against SARS-CoV2 in parents</measure>
    <time_frame>at inclusion</time_frame>
    <description>Ancillary study: Serology in parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Ab antiN and Ab anti-S1 and neutralization activity</measure>
    <time_frame>at inclusion</time_frame>
    <description>Ancillary study: Serology in parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive qPCR in parents</measure>
    <time_frame>at inclusion</time_frame>
    <description>Ancillary study: in parents, qualitative and quantitative measure , in nasopharynx, saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between different Ab and qPCR</measure>
    <time_frame>at inclusion</time_frame>
    <description>Ancillary study: in parents, qualitative and quantitative measure , in nasopharynx, saliva, Ab anti-N, Ab anti-S1, neutralization serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between antibody profile and viral clearance</measure>
    <time_frame>until 30 days post onset</time_frame>
    <description>Ancillary study: Serology in PCR positive parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>at Day 7</time_frame>
    <description>Ancillary study: Immune cells in positive PCR parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>at Day 15</time_frame>
    <description>Ancillary study: Immune cells in positive PCR parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>at Day 30</time_frame>
    <description>Ancillary study: Immune cells in positive PCR parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>at 6 months</time_frame>
    <description>Ancillary study: Immune cells in positive PCR parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ab profile and memory of immunity</measure>
    <time_frame>at 12 months</time_frame>
    <description>Ancillary study: Immune cells in positive PCR parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva biofluid characteristics of COVID-19 infected</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>in positive PCR parents: viral content (qPCR and immunodetection); presence of IgG, M, and A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of the virus</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>in positive PCR parents: nasopharynx, saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal immunity</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>in positive PCR parents: Ab anti-SARS-cov2 in nasopharynx samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection</measure>
    <time_frame>Until 1 year follow-up</time_frame>
    <description>in positive PCR parents: occurrence of reinfection, immunity responses during reinfection and potential mutations of the virus</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Hospitalized children or consulting at hospital</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents of one included child</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Children with potential COVID disease during the first wave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>serology test</intervention_name>
    <description>volume according to child weight</description>
    <arm_group_label>Children with potential COVID disease during the first wave</arm_group_label>
    <arm_group_label>Hospitalized children or consulting at hospital</arm_group_label>
    <arm_group_label>Parents of one included child</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nasopharyngeal swab</intervention_name>
    <description>nasopharyngeal swab for PCR</description>
    <arm_group_label>Children with potential COVID disease during the first wave</arm_group_label>
    <arm_group_label>Hospitalized children or consulting at hospital</arm_group_label>
    <arm_group_label>Parents of one included child</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rectal swab</intervention_name>
    <description>rectal swab for PCR</description>
    <arm_group_label>Children with potential COVID disease during the first wave</arm_group_label>
    <arm_group_label>Hospitalized children or consulting at hospital</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>saliva sample</intervention_name>
    <description>for biocollection</description>
    <arm_group_label>Children with potential COVID disease during the first wave</arm_group_label>
    <arm_group_label>Hospitalized children or consulting at hospital</arm_group_label>
    <arm_group_label>Parents of one included child</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For hospitalized children or consulting at hospital&#xD;
&#xD;
          -  any child over 7 days old and under 17 years hospitalized since at most 4 days Or any&#xD;
             child over 7 days old and under 17 years with a positive PCR at home, with a attending&#xD;
             physician in a participating centre&#xD;
&#xD;
          -  Parent's agreement for blood, saliva and stool samples&#xD;
&#xD;
          -  Optional parent's agreement for nasopharynx swab&#xD;
&#xD;
          -  Optional parent's agreement for follow-up if PCR+&#xD;
&#xD;
          -  With an Health insurance&#xD;
&#xD;
        For Children with potential COVID disease during the first wave&#xD;
&#xD;
          -  Any child over 7 days old and under 17 years, seropositive during the first wave&#xD;
&#xD;
          -  Or any child over 7 days old and under 17 years, with a previous inflammatory clinical&#xD;
             disease potentially linked to SARS-cov2&#xD;
&#xD;
          -  With an Health insurance&#xD;
&#xD;
        Parent of the enrolled child&#xD;
&#xD;
          -  One parent of the enrolled child on ped-covid&#xD;
&#xD;
          -  Agreement for blood and saliva samples&#xD;
&#xD;
          -  Optional agreement for nasopharynx swab&#xD;
&#xD;
          -  Optional parent's agreement for follow-up if PCR+&#xD;
&#xD;
          -  With an Health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For hospitalized children or consulting at hospital&#xD;
&#xD;
          -  child younger than 7 days&#xD;
&#xD;
          -  Refusal of parent&#xD;
&#xD;
          -  Refusal of child&#xD;
&#xD;
          -  No health insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle SERMET-GAUDELUS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique-Hôpitaux de Pars</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle SERMET-GAUDELUS, MD, PhD</last_name>
    <phone>+ 33 1 44 49 48 87</phone>
    <email>isabelle.sermet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly BRIAND, PhD</last_name>
    <phone>+ 33 1 44 38 18 62</phone>
    <email>nelly.briand@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital necker Enfants-Malades</name>
      <address>
        <city>¨Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle SERMET-GAUDELUS, MD,PhD</last_name>
      <phone>+ 33 1 44 49 48 87</phone>
      <email>isabelle.serme@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Child</keyword>
  <keyword>COVID-19 infection</keyword>
  <keyword>immune response</keyword>
  <keyword>healthy carrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

